Beta Adrenergic Antagonist for the Healing of Chronic DFU
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
One in four Veterans is affected by diabetes and will develop a diabetic foot ulcer. Diabetic
ulcers are very challenging to manage and are the most common cause of leg amputation. Many
advanced treatments are expensive and difficult to use in the clinic or at home. Those newer
therapies have shown little success in healing diabetic foot wounds. The investigators'
laboratory and animal work has suggested that a safe medication, currently used as an eye
drop for treatment of glaucoma, can heal these ulcers. The investigators are proposing to
test this drop (timolol) directly on the surface of the foot ulcer to see if can improve
healing faster than the current standard of care. To do this, the investigators propose a
"randomized controlled trial" with two groups of patients with diabetic foot ulcers: one will
receive standard of care with timolol while the other will receive standard of care with a
gel (hydrogel, as placebo medicine).